D. Ross Camidge, University of Colorado Anschutz Medical Campus (IMAGE)

University of Colorado Anschutz Medical Campus

D. Ross Camidge, University of Colorado Anschutz Medical Campus

Caption

D. Ross Camidge, MD, PhD and the ATOMIC consortium show that brigatinib remains effective even after first-line therapy with another next-generation ALK inhibitor.

Credit

University of Colorado Cancer Center

Usage Restrictions

None

License

Licensed content

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.